Cornea

Short-term steroid use can alleviate patient discomfort.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Kathryn A. Colby, MD, PhD, discusses Fuchs’ dystrophy symptoms and treatment options as well as the underlying concept of Descemet stripping only surgery and her role in pioneering this technique.

Equally important is that any symptoms of ocular allergies should be addressed to reduce the frequency of eye rubbing.

The company expects to have topline proof of concept data by the end of the first quarter of the year.

Robert L. Stamper, MD, speaks with Ophthalmology Times®' David Hutton on intraocular pressure measurement, corneal elasticity, and why hysteresis is important for glaucoma management.

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Presbyopia-correcting drops represent a whole new product category—one with a lot of upsides for clinicians who want to help their patients see well at all distances.

Moore suffered from dry eye disease and Lumenis noted that treatment with OptiLight improved her condition. Now she’s partnering with the company to share her story and empower others.

The FDA has approved the first generic of cyclosporine ophthalmic emulsion (Restasis; Allergan) 0.05% single-use vials of eye drops to increase tear production in patients with dry eye disease.

Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

The future of this age-related condition is bright and in focus.

A new treatment option may increase basal tear production in patients.

Renewed consumer interest in and demand for LASIK, SMILE, and other procedures are among the key drivers for 2021 performance.

Investigators find the prevalence of ocular surface tumors is greater in the North Central region of the United States.

According to the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories.

According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.

The application of mitomycin C after corneal cross-linking does not prevent development of corneal haze after the procedure, but it does contribute to development of more corneal haze.

Delayed presentations and acute shortage of donor corneal tissues for emergency keratoplasty are among reasons given for adverse outcome.

With every 10-year increase in patient age, the risk of the patients needing concomitant administration of steroid eye drops decreased by half, according to investigators.

A team of researchers from Thomas Jefferson University have found that immune cells could be doing much more than first thought in protecting our eyes.

Analysis finds acceptable outcomes can be expected when pterygium surgery is performed by a supervised ophthalmology resident.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.

Although graft rejection has not been associated with vaccinations, concern remains.

Impairment of corneal sensory innervation causes reduction of both protective reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound healing of the ocular surface.

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.